Search

Repligen Corp

Closed

SectorHealthcare

132.37 -3.86

Overview

Share price change

24h

Current

Min

131.74

Max

134.28

Key metrics

By Trading Economics

Income

-5M

8.3M

Sales

-3.7M

194M

P/E

Sector Avg

159.879

62.58

EPS

0.48

Profit margin

4.29

Employees

2,000

EBITDA

-13M

32M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+25.31% upside

Dividends

By Acuity

Next Earnings

28 Jul 2026

Market Stats

By TradingEconomics

Market Cap

1.5B

8.2B

Previous open

136.23

Previous close

132.37

News Sentiment

By Acuity

25%

75%

51 / 340 Healthcare

Repligen Corp Chart

Past performance is not a reliable indicator of future results.

Related News

24 Jul 2026, 19:06 UTC

News

Repligen Corp is under scrutiny as a stock to avoid, with concerns over its $763.3 million revenue and declining operating margins. Shares are trading lower today.

22 Jul 2026, 19:25 UTC

News
Event
Social Media

Repligen Corp is acquiring BioLife Solutions for about $1.5 billion, offering $11.25 in cash and stock, with a projected $20 million in synergies.

21 Jul 2026, 22:56 UTC

Repligen Corp shares are higher in after-market trading, despite a recent trend of lower closes. Broader market sentiment may be influenced by the Nikkei 225 surge.

20 Jul 2026, 18:06 UTC

Repligen Corp shares are higher today, reflecting positive market sentiment despite earlier intraday fluctuations. No specific news was identified to explain the movement.

Peer Comparison

Price change

Repligen Corp Forecast

Price Target

By TipRanks

25.31% upside

12 Months Forecast

Average 165.36 USD  25.31%

High 207 USD

Low 142 USD

Based on 14 Wall Street analysts offering 12 month price targets forRepligen Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

14 ratings

11

Buy

3

Hold

0

Sell

Sentiment

By Acuity

51 / 340 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Repligen Corp

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
help-icon Live chat